Home / Stocks / ACAD

ACADIA Pharmaceuticals (ACAD, Biotechnology) Stock Valuation & Fair Value Significantly overvalued

ACADIA Pharmaceuticals (ACAD, Biotechnology) trades at a blended P/E of 25.2, about 169% above its historical normal valuation, with a forward growth estimate of 8.8% and a PEG of 2.88. Analysts' one-year estimates have been hit 27% of the time. Priced at its historical normal P/E of 9.4 on the same blended earnings, the 2026-09-18 close of $27.29 corresponds to about $10.10 a share. This is a valuation reference, not a price target.

DATA AS OF 2026-09-21
Blended P/E
25.2
Normal P/E
9.4
PEG
2.88
Fwd growth
8.8%
Div yield
0.0%
RSI (14)
37.9
Neutral

The Street vs SeerForecast

Wall Street's mean price target for ACAD is $33.89 across 19 analysts, 33.3% above the current price. The average analyst rating is Buy. Our SeerForecast read of the same stock, formed without analyst targets: significantly overvalued. When the two disagree, start your digging there.

Valuation flags

Verdict history

tickerseer's rating has been significantly overvalued since 2026-07-31.

Blended P/E and rating by weekBlended P/E moved from 22.4 to 25.2 between 2026-07-31 and 2026-09-21, against a normal P/E of 9.4, with 0 rating changes over 18 recorded weeks.2026-07-31: P/E 22.4, Significantly overvalued (recalculated)2026-08-03: P/E 21.9, Significantly overvalued2026-08-07: P/E 21.9, Significantly overvalued (recalculated)2026-08-10: P/E 23.5, Significantly overvalued2026-08-14: P/E 23.5, Significantly overvalued (recalculated)2026-08-17: P/E 22.7, Significantly overvalued2026-08-21: P/E 22.7, Significantly overvalued (recalculated)2026-08-24: P/E 24.4, Significantly overvalued2026-08-27: P/E 24.4, Significantly overvalued (recalculated)2026-08-28: P/E 24.4, Significantly overvalued (recalculated)2026-08-30: P/E 24.4, Significantly overvalued (recalculated)2026-08-31: P/E 24.8, Significantly overvalued2026-09-05: P/E 24.8, Significantly overvalued (recalculated)2026-09-07: P/E 24.5, Significantly overvalued2026-09-12: P/E 24.5, Significantly overvalued (recalculated)2026-09-14: P/E 25.1, Significantly overvalued2026-09-19: P/E 25.1, Significantly overvalued (recalculated)2026-09-21: P/E 25.2, Significantly overvalued10.015.020.025.0Jul 31Aug 13Aug 26Sep 8Sep 21Normal P/E 9.4
Attractively valuedFairly valuedAbove fair valueLarger dot: a stronger reading

Not every point was recorded live. Points marked recalculated apply today's valuation rules to the metrics tickerseer archived that week.

Selected weeks: the first, the latest, and the cheapest and dearest.

WeekBlended P/EPremium to normal P/ERating
2026-07-31P/E 22.4+139%Significantly overvalued
2026-08-03P/E 21.9+134%Significantly overvalued
2026-09-21P/E 25.2+169%Significantly overvalued ← now

Frequently asked questions

Is ACADIA Pharmaceuticals stock overvalued?

At a blended P/E of 25.2 versus its historical normal P/E of 9.4, ACADIA Pharmaceuticals trades about 169% above its typical valuation, with a PEG of 2.88 on 8.8% forward growth. tickerseer currently rates it significantly overvalued.

What is ACADIA Pharmaceuticals's fair value and PEG?

ACADIA Pharmaceuticals trades at a blended P/E of 25.2 against a historical normal P/E of 9.4, a PEG of 2.88, and a forward growth estimate of 8.8%. Priced at its historical normal P/E of 9.4 on the same blended earnings, the 2026-09-18 close of $27.29 corresponds to about $10.10 a share. This is a valuation reference, not a price target.

Has tickerseer's rating of ACADIA Pharmaceuticals changed?

tickerseer's rating has been significantly overvalued since 2026-07-31.

What is the analyst price target for ACADIA Pharmaceuticals?

The mean Wall Street price target for ACADIA Pharmaceuticals is $33.89 across 19 analysts, 33.3% above the current price. tickerseer's SeerForecast verdict is formed independently of analyst targets.

Industry: Biotechnology. Create a free account to see the full analysis: the SeerAI score, its five quality sub-scores, valuation history, and the AI research note. Options setups and metric history are part of the paid plans.

See the full analysis →🔔 Track ACAD free: valuation & earnings alerts

Get the free weekly earnings preview

One email each Monday with the week's named earnings setups, the reasoning, and what settled last week. Strikes and sizing stay in Premium.

It's free, and you can unsubscribe any time. We also send a short product update once a month. Educational content, not investment advice.